A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects

Authors

Institutions

Publication Details

Journal
Drug Design Development and Therapy
Published
2025-03-01
DOI
https://doi.org/10.2147/dddt.s504814
Citations
2
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
2.59
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects

Xiaoyin Lai, Yangming Zhang, Yan Sai, Yun Liu et al.
2 citations
Drug Design Development and Therapy
Diabetes Treatment and Management
2.59
article

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects

Xiaoyin Lai, Yangming Zhang, Yan Sai, Yun Liu, Jingying Jia, Hongjie Qian, Chengyin Yu, Fajun Nan, Liyu Liang, Qian Chen, Zhifu Xie, Wei Li, Yifan Zhang, Jingya Li, Yating Wang, Yu Chen, Yanmei Liu
article en
2 citations

Abstract

No abstract available for this paper.
Drug Design Development and TherapyVol. Volume 19
Chinese Academy of Sciences (CN), Fudan University (CN), Shanghai Institute of Materia Medica (CN), Shanghai Xuhui Central Hospital (CN), Shanghai Clinical Research Center (CN), Regend Therapeutics (China) (CN)
Openalex Percentile: Top 11%
Diabetes Treatment and Management
2.59
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects — Xiaoyin Lai, Yangming Zhang, et al. · Drug Design Development and Therapy (2025) | TGRS Research Map | TGRS